|
Encainide
drug data and news
Encainide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Encainide
|
| Brand Names/Synonyms |
Encainida [Spanish]; Encainide; Encainide [French]; Encainidum [Latin]; Enkaid; MJ 9067; None |
| Indication |
For management of irregular heartbeats to a normal rhythm |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Used to treat irregular heartbeats. Encainide decreases excitability, conduction velocity, and automaticity as a result of slowed atrial, atrioventricular (AV) nodal, His-Purkinje, and intraventricular conduction. It causes a slight but significant prolongation of refractory periods in these tissues. The greatest effect is on the His-Purkinje system. Encainide decreases the rate of rise of the action potential without markedly affecting its duration. |
| Mechanism Of Action |
Encainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. |
Encainide News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Not Available |
| Drug_Category |
Antiarrhythmic Agents; ATC:C01BC08 |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
4-methoxy-N-[2-[1-methyl-2-(1-piperidyl)ethyl]phenyl]-benzamide |
| Chemical Formula |
C22H28N2O2 |
| Molecular Weight |
352.47 g/mol |
| Smiles String |
CC(CN1CCCCC1)C2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC |
| Melting Point |
Not Available |
| Water Solubility |
Not Available |
| State |
Solid |
| LogP/Hphobicity |
4.427 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
1-2 hours |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.drugs.com/cons/Encainide.html |
| Drug Type |
Approved Drug |
| Accession No |
APRD00613 |
| CAS Registry Number |
66778-36-7 |
| KEGG Compound ID |
C06978 |
| PubChem ID |
SID:9192 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
